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reamble
primary challenge in the development of clinical practice
uidelines is keeping pace with the stream of new data upon
hich recommendations are based. In an effort to respond
ore quickly to new evidence, the American College of
ardiology/American Heart Association (ACC/AHA)
ask Force on Practice Guidelines has created a new
focused update” process to revise the existing guideline
ecommendations that are affected by the evolving data or
pinion. Prior to the initiation of this focused approach,
eriodic updates and revisions of existing guidelines re-
uired up to 3 years to complete. Now, however, new
vidence will be reviewed in an ongoing fashion to more
fficiently respond to important science and treatment
rends that could have a major impact on patient outcomes
nd quality of care. Evidence will be reviewed at least twice
year and updates will be initiated on an as-needed basis as
uickly as possible, while maintaining the rigorous meth-
dology that the ACC and AHA have developed during
heir more than 20 years of partnership.
These updated guideline recommendations reflect a con-
ensus of expert opinion after a thorough review primarily of
ate-breaking clinical trials identified through a broad-based
etting process as being important to the relevant patient
opulation, and of other new data deemed to have an impact
n patient care (see Section 1.1 Evidence Review for details
egarding this focused update). It is important to note
hat this focused update is not intended to represent an
pdate based on a full literature review from the date
f the previous guideline publication. Specific criteria/
onsiderations for inclusion of new data include:
Publication in a peer-reviewed journal
Large, randomized, placebo-controlled trial(s)
Nonrandomized data deemed important on the basis of
results impacting current safety and efficacy assumptions
Strengths/weakness of research methodology and findings
Likelihood of additional studies influencing current findings iImpact on current performance measure(s) and/or like-
lihood of need to develop new performance measure(s)
Requests and requirements for review and update from
the practice community, key stakeholders, and other
sources free of relationships with industry or other
potential bias
Number of previous trials showing consistent results
Need for consistency with a new guideline or guideline
revision
In analyzing the data and developing updated recommen-
ations and supporting text, the Focused Update Writing
roup used evidence-based methodologies developed by the
CC/AHA Task Force on Practice Guidelines that are
escribed elsewhere (1,2). The schema for class of recommen-
ation and level of evidence is summarized in Table 1, which
lso illustrates how the grading system provides an estimate of
he size of the treatment effect and an estimate of the certainty
f the treatment effect. Note that a recommendation with level
f evidence B or C does not imply that the recommendation is
eak. Many important clinical questions addressed in guide-
ines do not lend themselves to clinical trials. Although
andomized trials may not be available, there may be a very
lear clinical consensus that a particular test or therapy is useful
nd effective. Both the class of recommendation and the level
f evidence listed in the focused updates are based on consid-
ration of the evidence reviewed in previous iterations of the
uideline, as well as the focused update. Of note, the implica-
ions of older studies that have informed recommendations but
ave not been repeated in contemporary settings are carefully
onsidered.
The ACC/AHA practice guidelines address patient
opulations (and healthcare providers) residing in North
merica. As such, drugs that are not currently available
n North America are discussed in the text without a
pecific class of recommendation. For studies performed
n large numbers of subjects outside of North America,
ach writing committee reviews the potential impact of
ifferent practice patterns and patient populations on the
reatment effect and on the relevance to the ACC/AHA
arget population to determine whether the findings
hould inform a specific recommendation.
The ACC/AHA practice guidelines are intended to assist
ealthcare providers in clinical decision making by describing a
ange of generally acceptable approaches for the diagnosis,
anagement, and prevention of specific diseases or conditions.
hey attempt to define practices that meet the needs of most
atients in most circumstances. The ultimate judgment regard-
ng care of a particular patient must be made by the healthcare
rovider and patient in light of all the circumstances presented
y that patient. Thus, there are circumstances in which deviations
rom these guidelines may be appropriate. Clinical decision
aking should consider the quality and availability of expertise in
he area where care is provided. These guidelines may be used as
he basis for regulatory or payer decisions, but the ultimate goal
s quality of care and serving the patient’s best interests.
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ecommendations are only effective if they are followed by
he patient. Because lack of patient adherence may adversely
ffect treatment outcomes, healthcare providers should
ake every effort to engage the patient in active participa-
ion with prescribed treatment.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflict of interest arising from industry relationships
r personal interests of a writing committee member. All
riting committee members and peer reviewers were re-
uired to provide disclosure statements of all such relation-
hips pertaining to the trials and other evidence under
onsideration (see Appendixes 1 and 2). Final recommen-
ations were balloted to all writing committee members.
riting committee members with significant (greater than
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpopu
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when wr
complete thought, such that a recommendation, even if separated and presented apart from
ull intent of the recommendation. It is hoped that this will increase readers’ comprehension of10 000) relevant relationships with industry were required To recuse themselves from voting on that recommendation.
hose writing committee members who did not participate
re not listed as authors of this focused update.
With the exception of the recommendations presented
ere, the full guideline remains current. Only the recom-
endations from the affected sections of the full guide-
ine are included in this focused update. For easy refer-
nce, all recommendations from any section of a
uideline impacted by a change are presented with
otation as to whether they remain current, are new, or
ave been modified. When evidence impacts recommen-
ations in more than 1 guideline, those guidelines are
pdated concurrently.
The recommendations in this focused update will be
onsidered current until they are superseded by another
ocused update or until the full-text guidelines are revised.
vidence†
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
commendations. All guideline recommendations have been written in full sentences that express
t of the document (including headings above sets of recommendations), would still convey the
idelines and will allow queries at the individual recommendation level.l of E
lations
at the r
e a ver
iting rehis focused update is published in the December 4, 2007,
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December 4, 2007:2264–74 Chronic Angina Focused Updatessue of the Journal of the American College of Cardiology and
he December 4, 2007, issue of Circulation as an update to
he full-text guideline and is also posted on the ACC
www.acc.org) and AHA (www.americanheart.org) World
ide Web sites. Copies of the focused update are available
rom both organizations.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice-Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Evidence Review
ate-breaking clinical trials presented at the 2005 and
006 annual scientific meetings of the ACC, AHA, and
uropean Society of Cardiology, as well as selected other
ata published during the same time period, were re-
iewed by the standing guideline writing committee
long with the parent Task Force and other experts to
dentify those trials and other key data that might impact
uideline recommendations. On the basis of the criteria/
onsiderations noted above, recent trial data and other
linical information were considered when deciding
hether there was evidence important enough to prompt
focused update of the 2002 ACC/AHA Guidelines for
he Management of Patients With Chronic Stable An-
ina (3–9). After consideration and evaluation of the
riteria, the 2006 AHA Guidelines for Secondary Pre-
ention for Patients With Coronary and Other Athero-
clerotic Vascular Disease (8) were considered important
nough to prompt this focused update.
This focused update of the ACC/AHA 2002 Guide-
ine Update for the Management of Patients With
hronic Stable Angina spotlights the 2006 AHA/ACC
uidelines for Secondary Prevention for Patients With
oronary and Other Atherosclerotic Vascular Disease.
nly recommendations related to secondary prevention
n patients with chronic angina have been revised. In
eptember 2007, the ACC/AHA Task Force on Practice
uidelines convened a writing committee to revise the
ull guideline for the management of patients with stable
schemic heart disease. This writing committee will
onsider all the recent evidence, including late-breaking
linical trials recently presented.
Consult the full-text version or executive summary of the
CC/AHA 2002 Guideline Update for the Management
f Patients With Chronic Stable Angina for policy on
linical areas not covered by the focused update (10).
ndividual recommendations updated in this focused update
ill be incorporated into future revisions and/or updates of
he full-text guidelines..2. Organization of Committee and
elationships With Industry
or this focused update, all members of the 2002 Chronic
ngina Writing Committee were invited to participate;
hose who agreed (referred to as the 2007 Focused
pdate Writing Group) were required to disclose all
elationships with industry relevant to the data under
onsideration (2). Focused Update Writing Group mem-
ers who had no significant relevant relationships with
ndustry authored the first draft of the focused update;
he draft was then reviewed and revised by the full writing
roup. Each recommendation required a confidential vote
y the writing group members prior to external review of
he document. Any writing committee member with a
ignificant (greater than $10 000) relationship with
ndustry relevant to the recommendation was recused
rom voting on that recommendation.
.3. Review and Approval
his document was reviewed by 2 official reviewers
ominated by the ACC and 2 official reviewers nomi-
ated by the AHA, as well as 1 reviewer from the ACC
ardiac Catheterization and Intervention Committee
nd 16 content reviewers. All reviewer relationship with
ndustry information was collected and distributed to the
riting committee and is published in this document (see
ppendix 2 for details).
This document was approved for publication by the
overning bodies of the American College of Cardiology
oundation and the AHA.
taff
merican College of Cardiology Foundation
ohn C. Lewin, MD, Chief Executive Officer
harlene May, Director, Clinical Policy and Documents
isa Bradfield, Associate Director, Practice Guidelines
ark D. Stewart, MPH, Associate Director, Evidence-
ased Medicine
ue Keller, BSN, MPH, Senior Specialist, Evidence-Based
edicine
ita Washington, MSA, Specialist, Practice Guidelines
rin A. Barrett, Senior Specialist, Clinical Policy and
ocuments
merican Heart Association
. Cass Wheeler, Chief Executive Officer
ose Marie Robertson, MD, FACC, FAHA, Chief
cience Officer
athryn A. Taubert, PhD, FAHA, Senior Scientist
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2002 Chronic Angina Recommendations 2007 Chronic Angina Recommendations
2007 COR
and LOE Comments
Smoking
ssess tobacco use. Strongly encourage patient and
family to stop smoking and to avoid second-hand
smoke. Provide counseling, pharmacological
therapy (including nicotine replacement and
buproprion), and formal cessation programs as
appropriate.
Smoking cessation and avoidance of exposure to
environmental tobacco smoke at work and home is
recommended. Follow-up, referral to special programs,
and/or pharmacotherapy (including nicotine replacement)
is recommended, as is a stepwise strategy for smoking
cessation (Ask, Advise, Assess, Assist, Arrange).
I (B) Modified recommendation
(changed text and COR
LOE added)
Blood Pressure Control
nitiate lifestyle modification (weight control, physical
activity, alcohol moderation, moderate sodium
restriction, and emphasis on fruits, vegetables, and
low-fat dairy products) in all patients with blood
pressure greater than or equal to 130 mm Hg
systolic or 80 mm Hg diastolic. Add blood pressure
medication, individualized to other patient
requirements and characteristics (i.e., age, race,
need for drugs with specific benefits) if blood
pressure is not less than 140 mm Hg systolic or 90
mm Hg diastolic, or if blood pressure is not less
than 130 mm Hg systolic or 85 mm Hg diastolic for
individuals with heart failure or renal insufficiency
(less than 80 mm Hg diastolic for individuals with
diabetes).
Patients should initiate and/or maintain lifestyle
modifications—weight control; increased physical activity;
moderation of alcohol consumption; limited sodium
intake; and maintenance of a diet high in fresh fruits,
vegetables, and low-fat dairy products.
Blood pressure control according to Joint National
Conference VII guidelines is recommended (i.e., blood
pressure less than 140/90 mm Hg or less than 130/80
mm Hg for patients with diabetes or chronic kidney
disease) (11).
For hypertensive patients with well established coronary
artery disease, it is useful to add blood pressure
medication as tolerated, treating initially with beta
blockers and/or ACE inhibitors, with addition of other
drugs as needed to achieve target blood pressure.
I (B)
I (A)
I (C)
Modified recommendation
(changed text and COR
LOE added)
New recommendation
New recommendation
Lipid Management
tart dietary therapy in all patients (less than 7%
saturated fat and less than 200 mg per dL
cholesterol) and promote physical activity and
weight management. Encourage increased
consumption of omega-3 fatty acids.
Dietary therapy for all patients should include reduced intake
of saturated fats (to less than 7% of total calories), trans-
fatty acids, and cholesterol (to less than 200 mg per day).
Adding plant stanol/sterols (2 g per day) and/or viscous fiber
(greater than 10 g per day) is reasonable to further lower
LDL-C.
Daily physical activity and weight management are
recommended for all patients.
I (B)
IIa (A)
I (B)
Modified recommendation
(changed text and COR
LOE added)
New recommendation
New recommendation
onsider omega-3 fatty acids as adjunct for high TG. For all patients, encouraging consumption of omega-3 fatty
acids in the form of fish* or in capsule form (1 g per day)
for risk reduction may be reasonable. For treatment of
elevated TG, higher doses are usually necessary for risk
reduction.
IIb (B) Modified recommendation
(changed text and COR
LOE added)
ssess fasting lipid profile in all patients, and within
24 hours of hospitalization for those with an
acute event. If patients are hospitalized, consider
adding drug therapy on discharge. Add drug
therapy according to the following guide:
Recommended lipid management includes assessment of a
fasting lipid profile.
I (A) Modified recommendation
(changed text and COR
LOE added)
DL less than 100 mg per dL (baseline or on-
treatment). Further LDL-lowering therapy not
required. Consider fibrate or niacin (if low HDL or
high TG).
a. LDL-C should be less than 100 mg per dL and
b. Reduction of LDL-C to less than 70 mg per dL or high-dose
statin therapy is reasonable.
I (A)
IIa (A)
Modified recommendation
(changed text and COR
LOE added)
New recommendation
DL 100 to 129 mg per dL (baseline or on-
treatment) Therapeutic options: Intensify LDL-
lowering therapy (statin or resin†). Fibrate or
niacin (if low HDL or high TG). Consider combined
drug therapy (statin  fibrate or niacin) (if low
HDL or high TG).
c. If baseline LDL-C is greater than or equal to 100 mg per
dL, LDL-lowering drug therapy should be initiated in
addition to therapeutic lifestyle changes. When LDL-
lowering medications are used in high-risk or moderately
high-risk persons, it is recommended that intensity of
therapy be sufficient to achieve a 30% to 40% reduction in
LDL-C levels.
I (A) Modified recommendation
(changed text and COR
LOE added)
DL greater than or equal to 130 mg per dL
(baseline or on-treatment). Intensify LDL-lowering
therapy (statin or resin†). Add or increase drug
therapy with lifestyle therapies.
d. If on-treatment LDL-C is greater than or equal to 100 mg
per dL, LDL-lowering drug therapy should be intensified.
e. If baseline LDL-C is 70 to 100 mg per dL, it is reasonable
to treat LDL-C to less than 70 mg per dL.
I (A)
IIa (B)
Modified recommendation
(changed text and COR
LOE added)
New recommendationContinued on next page
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2002 Chronic Angina Recommendations 2007 Chronic Angina Recommendations
2007 COR
and LOE Comments
f TG 200 to 499 mg per dL: Consider fibrate or
niacin after LDL-lowering therapy.†
f. If TG are 200 to 499 mg per dL, non–HDL-C‡ should be
less than 130 mg per dL and
I (B) Modified recommendation
(changed text and COR
LOE added)
g. Further reduction of non–HDL-C‡ to less than 100 mg per
dL is reasonable, if TG are greater than or equal to 200 to
499 mg per dL.
IIa (B) New recommendation
h. Therapeutic options to reduce non–HDL-C are:
● Niacin can be useful as a therapeutic option to reduce
non–HDL-C (after LDL-C–lowering therapy)§ or
● Fibrate therapy as a therapeutic option can be useful to
reduce non–HDL-C‡ (after LDL-C–lowering therapy).
IIa (B)
New recommendation
f TG greater than or equal to 500 mg per dL:
Consider fibrate or niacin before LDL-lowering
therapy.*
i. If TG are greater than or equal to 500 mg per dL,
therapeutic options to lower the TG to reduce the risk of
pancreatitis are fibrate or niacin; these should be initiated
before LDL-C lowering therapy. The goal is to achieve non–
HDL-C‡ less than 130 mg per dL if possible.
I (C) Modified recommendation
(changed text and COR
LOE added)
The following lipid management strategies can be beneficial: IIa (C)
a. If LDL-C less than 70 mg per dL is the chosen target,
consider drug titration to achieve this level to minimize
side effects and cost. When LDL-C less than 70 mg per dL
is not achievable because of high baseline LDL-C levels, it
generally is possible to achieve reductions of greater than
50% in LDL-C levels by either statins or LDL-C–lowering
drug combinations. (12)
f TG greater than or equal to 150 mg per dL or HDL
less than 40 mg per dL: Emphasize weight
management and physical activity. Advise
smoking cessation.
Deleted recommendation
Drug combinations are beneficial for patients on lipid
lowering therapy who are unable to achieve LDL-C less
than 100 mg per dL.
I (C) New recommendation
Physical Activity
ssess risk, preferably with exercise test, to guide
prescription. Encourage minimum of 30 to 60
minutes of activity, preferably daily, or at least 3
or 4 times weekly (walking, jogging, cycling, or
other aerobic activity) supplemented by an
increase in daily lifestyle activities (e.g., walking
breaks at work, gardening, household work).
Physical activity of 30 to 60 minutes, 7 days per week
(minimum 5 days per week) is recommended. All patients
should be encouraged to obtain 30 to 60 minutes of
moderate-intensity aerobic activity, such as brisk walking,
on most, preferably all, days of the week, supplemented
by an increase in daily activities (such as walking breaks
at work, gardening, or household work).
I (B) Modified recommendation
(changed text and COR
LOE added)
The patient’s risk should be assessed with a physical activity
history. Where appropriate, an exercise test is useful to
guide the exercise prescription (see Exercise Testing
Guideline) (10).
I (B) New recommendation
dvise medically supervised programs for
moderate- to high-risk patients.
Medically supervised programs (cardiac rehabilitation) are
recommended for at-risk patients (e.g., recent acute
coronary syndrome or revascularization, heart failure).
I (B) Modified recommendation
(changed text and COR
LOE added)
Expanding physical activity to include resistance training on 2
days per week may be reasonable.
IIb (C) New recommendationContinued on next page
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2002 Chronic Angina Recommendations 2007 Chronic Angina Recommendations
2007 COR
and LOE Comments
Weight Management
alculate BMI and measure waist circumferences
as part of evaluation. Monitor response of BMI
and waist circumference to therapy. Start weight
management and physical activity as
appropriate. Desirable BMI range is 18.5 to 24.9
kg/m2.
BMI and waist circumference should be assessed regularly.
On each patient visit, it is useful to consistently encourage
weight maintenance/reduction through an appropriate
balance of physical activity, caloric intake, and formal
behavioral programs when indicated to achieve and
maintain a BMI between 18.5 and 24.9 kg/m2.
I (B) Modified recommendation
(changed text and COR
LOE added)
hen BMI greater than or equal to 25 kg/m2, goal
for waist circumference is less than or equal to
40 inches (102 cm) in men and less than or
equal to 35 inches (89 cm) in women.
If waist circumference is greater than or equal to 35 inches
(89 cm) in women or greater than or equal to 40 inches
(102 cm) in men, it is beneficial to initiate lifestyle
changes and consider treatment strategies for metabolic
syndrome as indicated. Some male patients can develop
multiple metabolic risk factors when the waist
circumference is only marginally increased (e.g., 37 to 40
inches [94 to 102 cm]). Such persons may have a strong
genetic contribution to insulin resistance. They should
benefit from changes in life habits, similarly to men with
categorical increases in waist circumference.
I (B) Modified recommendation
(changed text and COR
LOE added)
tart weight management and physical activity as
appropriate. Desirable BMI range is 18.5 to 24.9
kg/m2.
The initial goal of weight loss therapy should be to gradually
reduce body weight by approximately 10% from baseline.
With success, further weight loss can be attempted if
indicated through further assessment.
I (B) Modified recommendation
(changed text and COR
LOE added)
Diabetes Management
ppropriate hypoglycemic therapy to achieve near-
normal fasting plasma glucose, as indicated by
HbA1c.
Diabetes management should include lifestyle and
pharmacotherapy measures to achieve a near-normal
HbA1c.
I (B) Modified recommendation
(changed text and COR
LOE added)
reatment of other risks (e.g., physical activity,
weight management, blood pressure, and
cholesterol management).
Vigorous modification of other risk factors (e.g., physical
activity, weight management, blood pressure control, and
cholesterol management) as recommended should be
initiated and maintained.
I (B) Modified recommendation
(changed text and COR
LOE added)
Antiplatelet Agents/Anticoagulants
tart and continue indefinitely aspirin 75 to 325 mg
per day if not contraindicated. Consider clopidogrel
as an alternative if aspirin contraindicated.
Aspirin should be started at 75 to 162 mg per day and
continued indefinitely in all patients unless
contraindicated.
I (A) Modified recommendation
(changed text and COR
LOE added)
anage warfarin to international normalized ratio 
2.0 to 3.0 in post-MI patients when clinically
indicated or for those not able to take aspirin or
clopidogrel.
Use of warfarin in conjunction with aspirin and/or clopidogrel
is associated with an increased risk of bleeding and
should be monitored closely.
I (B) Modified recommendation
(changed text and COR
LOE added)
Renin-Angiotensin-Aldosterone System Blockers
CE Inhibitors
reat all patients indefinitely post-MI; start early in
stable high-risk patients (anterior MI, previous
MI, Killip class II [S3, gallop, rales, radiographic
CHF]). Consider chronic therapy for all other
patients with coronary or other vascular disease
unless contraindicated.
ACE inhibitors should be started and continued indefinitely in
all patients with left ventricular ejection fraction less than
or equal to 40% and in those with hypertension, diabetes,
or chronic kidney disease unless contraindicated.
I (A) Modified recommendation
(changed text and COR
LOE added)
se as needed to manage blood pressure or
symptoms in all other patients.
ACE inhibitors should be started and continued indefinitely in
patients who are not lower risk (lower risk defined as
those with normal left ventricular ejection fraction in
whom cardiovascular risk factors are well controlled and
revascularization has been performed), unless
contraindicated.
I (B) Modified recommendation
(changed text and COR
LOE added)
It is reasonable to use ACE inhibitors among lower-risk
patients with mildly reduced or normal left ventricular
ejection fraction in whom cardiovascular risk factors are
well controlled and revascularization has been performed.
IIa (B) New recommendation
Continued on next page
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